Dr. McGregor on Choosing Combo Regimens in Advanced RCC

Video

In Partnership With:

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses how to choose between combination treatments in advanced renal cell carcinoma.

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses how to choose between combination treatments in advanced renal cell carcinoma (RCC).

Three combinations, nivolumab (Opdivo) and ipilimumab (Yervoy), pembrolizumab (Keytruda) and axitinib (Inlyta), and axitinib and avelumab (Bavencio), were shown to be superior to sunitinib (Sutent) in clinical trials. However, these combinations have not been compared to one another, which poses a potential challenge in choosing between them in practice, says McGregor.

Although well tolerated, the combination of axitinib and avelumab has not yet shown an overall survival (OS) benefit in the frontline setting, explains McGregor. He adds that nivolumab and ipilimumab has mainly shown benefit in patients with intermediate- and poor-risk disease while pembrolizumab and axitinib was effective in all risk groups.

Ultimately, it comes down to patient preference, says McGregor. Avelumab and axitinib has reported an almost 10% complete response rate but with significant adverse events, which can be deterring for patients. Some patients may decide against a particular combination due to the potential immune-related adverse events or because an oral medication is preferred, he adds.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD